EFTA00309574Set 9
2014-04-282p1,111w
relatively small at only $0.8bn in PD-LI high patients, the Richard Vosser AC
Roche data should serve to further highlight the immuno-onocolgy
opportunity. Beyond bladder cancer data ... this report as only a single
factor in making their investment decision.
wvolijpmorganmarkets.com
EFTA00309574
Richard Vosser Europe Equity Research
28 Aprd 2014
IPMorgan CAZENOVE
Executive Summary
Going into ASCO where
https://www.justice.gov/epstein/files/DataSet%209/EFTA00309574.pdf